Cargando…
Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
Since the end of 2019, the outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic. There is an urgent need for effective and low-toxic antiviral drugs to remedy Remdesivir’s limitation. Hydroxychloroquine, a broad spectrum anti-viral drug, showed...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606320/ https://www.ncbi.nlm.nih.gov/pubmed/34875467 http://dx.doi.org/10.1016/j.bmc.2021.116523 |
_version_ | 1784602320238018560 |
---|---|
author | Ni, Yong Liao, Jinbiao Qian, Zhenlong Wu, Chunxiu Zhang, Xiangyu Zhang, Ji Xie, Youhua Jiang, Sheng |
author_facet | Ni, Yong Liao, Jinbiao Qian, Zhenlong Wu, Chunxiu Zhang, Xiangyu Zhang, Ji Xie, Youhua Jiang, Sheng |
author_sort | Ni, Yong |
collection | PubMed |
description | Since the end of 2019, the outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic. There is an urgent need for effective and low-toxic antiviral drugs to remedy Remdesivir’s limitation. Hydroxychloroquine, a broad spectrum anti-viral drug, showed inhibitory activity against SARS-CoV-2 in some studies. Thus, we adopted a drug repurposing strategy, and further investigated hydroxychloroquine. We obtained different configurations of hydroxychloroquine side chains by using chiral resolution technique, and successfully furnished R-/S-hydroxychloroquine sulfate through chemical synthesis. The R configuration of hydroxychloroquine was found to exhibit higher antiviral activity (EC50 = 3.05 μM) and lower toxicity in vivo. Therefore, R-HCQ is a promising lead compound against SARS-CoV-2. Our research provides new strategy for the subsequent research on small molecule inhibitors against SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8606320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86063202021-11-22 Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro Ni, Yong Liao, Jinbiao Qian, Zhenlong Wu, Chunxiu Zhang, Xiangyu Zhang, Ji Xie, Youhua Jiang, Sheng Bioorg Med Chem Article Since the end of 2019, the outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic. There is an urgent need for effective and low-toxic antiviral drugs to remedy Remdesivir’s limitation. Hydroxychloroquine, a broad spectrum anti-viral drug, showed inhibitory activity against SARS-CoV-2 in some studies. Thus, we adopted a drug repurposing strategy, and further investigated hydroxychloroquine. We obtained different configurations of hydroxychloroquine side chains by using chiral resolution technique, and successfully furnished R-/S-hydroxychloroquine sulfate through chemical synthesis. The R configuration of hydroxychloroquine was found to exhibit higher antiviral activity (EC50 = 3.05 μM) and lower toxicity in vivo. Therefore, R-HCQ is a promising lead compound against SARS-CoV-2. Our research provides new strategy for the subsequent research on small molecule inhibitors against SARS-CoV-2. Elsevier Ltd. 2022-01-01 2021-11-22 /pmc/articles/PMC8606320/ /pubmed/34875467 http://dx.doi.org/10.1016/j.bmc.2021.116523 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Ni, Yong Liao, Jinbiao Qian, Zhenlong Wu, Chunxiu Zhang, Xiangyu Zhang, Ji Xie, Youhua Jiang, Sheng Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro |
title | Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro |
title_full | Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro |
title_fullStr | Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro |
title_full_unstemmed | Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro |
title_short | Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro |
title_sort | synthesis and evaluation of enantiomers of hydroxychloroquine against sars-cov-2 in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606320/ https://www.ncbi.nlm.nih.gov/pubmed/34875467 http://dx.doi.org/10.1016/j.bmc.2021.116523 |
work_keys_str_mv | AT niyong synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro AT liaojinbiao synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro AT qianzhenlong synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro AT wuchunxiu synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro AT zhangxiangyu synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro AT zhangji synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro AT xieyouhua synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro AT jiangsheng synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro |